January 2, 2025 02:15 PM EST

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Zachary Brennan

Senior Editor

The FDA’s Cardiovascular and Renal Drugs Advisory Committee is set to meet Feb. 24 to discuss Novartis’ latest submission of Fabhalta in an ultra-rare kidney …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Zachary Brennan

Senior Editor

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

No­vo pe­ti­tions FDA over Vic­toza com­pound­ing as first gener­ic wins ap­proval

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval